Medios reported preliminary earnings results for the full year ended December 31, 2017. For the year, sales revenue increased by 58% to EUR 253.0 million compared to the prior-year period (prior year EUR 160.4 million, pro-forma IFRS). Earnings before taxes (EBT) and special effects rose by 38% to EUR 8.0 million (prior year EUR 5.8 million, pro-forma IFRS). The Management Board had expected consolidated sales revenue amounting to EUR 230 million and an EBT before special effects amounting to EUR 7.0 million up to EUR 7.5 million. The increase in consolidated sales revenue resulted essentially from gaining market share through the further expansion of the partner network as well as the extension of the product range in the Specialty Pharma field. The EBT takes into account negative impacts from growth investments and the prohibition of public tendering on cytostatic drugs as well as the effects of the new drug price regulation on oncological preparations.

For the fiscal year 2018, the Management Board is optimistic.